Some of this information is incorrect. The Eliquis patent is not close to expiring. Field promotion of Eliquis has several more years. This is not a replacement for Eliquis. Eliquis field reps are not doing half their calls virtually. The expectation is around 15% but right now that percentage is not being reached. Pfizer also has a much smaller field force for womens health products. The Cardiology and Womens Health field forces are a combined total of about 750 reps nationally. All reps have single accountability territories.
The Tampa and Chicago call centers are calling on low value targets and targets who reside in areas where there is no field force presence. The jury is out on how effective this will be. Pfizer has made a huge investment in remote selling.
Pfizer had previously entered into a licensing agreement with Biohaven to promote Nurtec ODT in many markets outside of the USA. Pfizer has always been flush with cash but now even more so. This deal is all about adding product to fill pipeline gaps. At this point who knows how many Biohaven representatives are affected but I wouldn’t necessarily say it will be everyone.
